Cargando…

Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously

BACKGROUND: While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, there is a paucity of data regarding elective shoulder arthroplasty. METHODS: Fifty-eight patients were identified who underwent primary anatomic total shoulder arthroplasty (TSA) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Thomas H., Labott, Joshua R., Austin, Daniel C., Barlow, Jonathan D., Morrey, Mark E., Sanchez-Sotelo, Joaquin, Sperling, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091745/
https://www.ncbi.nlm.nih.gov/pubmed/35572450
http://dx.doi.org/10.1016/j.jseint.2022.01.008
_version_ 1784704995985195008
author Rogers, Thomas H.
Labott, Joshua R.
Austin, Daniel C.
Barlow, Jonathan D.
Morrey, Mark E.
Sanchez-Sotelo, Joaquin
Sperling, John W.
author_facet Rogers, Thomas H.
Labott, Joshua R.
Austin, Daniel C.
Barlow, Jonathan D.
Morrey, Mark E.
Sanchez-Sotelo, Joaquin
Sperling, John W.
author_sort Rogers, Thomas H.
collection PubMed
description BACKGROUND: While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, there is a paucity of data regarding elective shoulder arthroplasty. METHODS: Fifty-eight patients were identified who underwent primary anatomic total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty while prescribed clopidogrel. There were 33 (57%) reverse shoulder arthroplasties and 25 (43%) TSAs performed. Patients were separated into two groups based upon their use of clopidogrel in the preoperative period. Twenty patients (35%; group 1) continued clopidogrel through surgery, and 38 patients (65%; group 2) did not. The mean age was 74 years, and the mean follow-up was 42 months. RESULTS: Both groups demonstrated substantial improvements in pain and motion: visual analog scale pain improved by 7 points (P < .001), elevation by 71° (P < .001), external rotation by 29° (P < .001), and internal rotation by 1.7 points (P < .001), with no significant difference between groups. At the final follow-up, the mean American Shoulder and Elbow Surgeons score was 77 in group 1 and 86 in group 2 (P = .067, minimum clinically important difference = 9). Estimated blood loss was 176 mL in group 1 and 127 in group 2 (P = .02). There was one transfusion in group 1 (5%) and 0 in group 2 (P = .16). The 90-day complication rates were 3/20 (15%) in group 1 and 0/37 in group 2 (hazard ratio = 13, P = .14). There was no statistically significant difference between groups for 30-day adverse cardiac events (2.6% and 0%, respectively, P = .46). CONCLUSION: For the patients who continued clopidogrel preoperatively, estimated blood loss was significantly higher and trended toward a lower American Shoulder and Elbow Surgeons score (with differences meeting the minimum clinically important difference) and a higher 90-day complication rate. Perioperative continuation of clopidogrel in shoulder arthroplasty should be approached cautiously.
format Online
Article
Text
id pubmed-9091745
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90917452022-05-12 Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously Rogers, Thomas H. Labott, Joshua R. Austin, Daniel C. Barlow, Jonathan D. Morrey, Mark E. Sanchez-Sotelo, Joaquin Sperling, John W. JSES Int Shoulder BACKGROUND: While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, there is a paucity of data regarding elective shoulder arthroplasty. METHODS: Fifty-eight patients were identified who underwent primary anatomic total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty while prescribed clopidogrel. There were 33 (57%) reverse shoulder arthroplasties and 25 (43%) TSAs performed. Patients were separated into two groups based upon their use of clopidogrel in the preoperative period. Twenty patients (35%; group 1) continued clopidogrel through surgery, and 38 patients (65%; group 2) did not. The mean age was 74 years, and the mean follow-up was 42 months. RESULTS: Both groups demonstrated substantial improvements in pain and motion: visual analog scale pain improved by 7 points (P < .001), elevation by 71° (P < .001), external rotation by 29° (P < .001), and internal rotation by 1.7 points (P < .001), with no significant difference between groups. At the final follow-up, the mean American Shoulder and Elbow Surgeons score was 77 in group 1 and 86 in group 2 (P = .067, minimum clinically important difference = 9). Estimated blood loss was 176 mL in group 1 and 127 in group 2 (P = .02). There was one transfusion in group 1 (5%) and 0 in group 2 (P = .16). The 90-day complication rates were 3/20 (15%) in group 1 and 0/37 in group 2 (hazard ratio = 13, P = .14). There was no statistically significant difference between groups for 30-day adverse cardiac events (2.6% and 0%, respectively, P = .46). CONCLUSION: For the patients who continued clopidogrel preoperatively, estimated blood loss was significantly higher and trended toward a lower American Shoulder and Elbow Surgeons score (with differences meeting the minimum clinically important difference) and a higher 90-day complication rate. Perioperative continuation of clopidogrel in shoulder arthroplasty should be approached cautiously. Elsevier 2022-02-13 /pmc/articles/PMC9091745/ /pubmed/35572450 http://dx.doi.org/10.1016/j.jseint.2022.01.008 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Shoulder
Rogers, Thomas H.
Labott, Joshua R.
Austin, Daniel C.
Barlow, Jonathan D.
Morrey, Mark E.
Sanchez-Sotelo, Joaquin
Sperling, John W.
Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously
title Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously
title_full Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously
title_fullStr Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously
title_full_unstemmed Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously
title_short Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously
title_sort perioperative clopidogrel (plavix) continuation in shoulder arthroplasty: approach cautiously
topic Shoulder
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091745/
https://www.ncbi.nlm.nih.gov/pubmed/35572450
http://dx.doi.org/10.1016/j.jseint.2022.01.008
work_keys_str_mv AT rogersthomash perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously
AT labottjoshuar perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously
AT austindanielc perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously
AT barlowjonathand perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously
AT morreymarke perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously
AT sanchezsotelojoaquin perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously
AT sperlingjohnw perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously